Expertise in
12
conditions

Dr. Mehmet F. Okcu

Hematology | Oncology
Office
6701 Fannin St Fl 14, 
Houston, TX 
Accepting New Patients
Expertise in
12
conditions
Office
6701 Fannin St Fl 14, 
Houston, TX 

Overview

Mehmet Okcu is a Hematologist and an Oncologist practicing medicine in Houston, Texas.

Dr. Okcu is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Rhabdomyosarcoma, Posterior Fossa Tumor, and Embryonal Tumor with Multilayered Rosettes.

He is actively involved in clinical research, co-authoring 109 peer reviewed articles and participating in 4 clinical trials. Dr. Okcu is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

Office
6701 Fannin St Fl 14, Houston, TX 77030

Additional Areas of Focus

Dr. Okcu has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Enrollment Status: Completed
Publish Date: August 26, 2024
Intervention Type: Procedure, Other
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
View 3 Less Clinical Trials

109 Total Publications

Integrating a Project-Based Learning Methodology into a Department-Wide Quality Improvement Curriculum: A Nine-Year Experience in Pediatric Subspecialty Training.
Integrating a Project-Based Learning Methodology into a Department-Wide Quality Improvement Curriculum: A Nine-Year Experience in Pediatric Subspecialty Training.
Journal: Journal of medical education and curricular development
Published: October 30, 2025
Similar Doctors
Expertise in
27
conditions
Dr. William G. Wierda
Hematology | Oncology
Expertise in
27
conditions
Dr. William G. Wierda
Hematology | Oncology
Referral may be required

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.1 miles away)
713-792-7040
Languages Spoken:
English
See accepted insurances

William Wierda is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Wierda is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
22
conditions
Dr. Murali M. Chintagumpala
Hematology | Oncology
Expertise in
22
conditions
Dr. Murali M. Chintagumpala
Hematology | Oncology
Referral may be required

Baylor College Of Medicine

6701 Fannin St, 
Houston, TX 
 (0.1 miles away)
832-822-4242
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Murali Chintagumpala is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Chintagumpala is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Gliomatosis Cerebri, Brain Tumor, Posterior Fossa Tumor, and Nephrectomy. Dr. Chintagumpala is currently accepting new patients.

Expertise in
12
conditions
Dr. Carl E. Allen
Hematology | Oncology
Expertise in
12
conditions
Dr. Carl E. Allen
Hematology | Oncology
Referral may be required

Office

1102 Bates Ave Ste 750, 
Houston, TX 
 (0.1 miles away)
832-824-4312
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carl Allen is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Allen is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Hemophagocytic Lymphohistiocytosis, and Bone Marrow Transplant. Dr. Allen is currently accepting new patients.

Frequently Asked Questions about Dr. Mehmet F. Okcu

How do I make an appointment with Dr. Mehmet F. Okcu?

You can book an appointment with Dr. Mehmet F. Okcu by calling their office at 832-822-4240. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mehmet F. Okcu a top-rated expert for Medulloblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mehmet F. Okcu is classified as an Distinguished expert for Medulloblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mehmet F. Okcu specialize in?

While Dr. Mehmet F. Okcu is a Hematology, they have specific expertise in Medulloblastoma, Rhabdomyosarcoma, and Posterior Fossa Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mehmet F. Okcu participate in research or clinical trials?

Yes. Dr. Mehmet F. Okcu has published 109 articles and abstracts on conditions like Medulloblastoma. You can view a list of Dr. Mehmet F. Okcu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mehmet F. Okcu accept my insurance?

Dr. Mehmet F. Okcu accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 832-822-4240 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Okcu's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile